IRIS
PIERANTOZZI, MARIANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 47.584
EU - Europa 4.034
AS - Asia 609
Continente sconosciuto - Info sul continente non disponibili 22
SA - Sud America 15
OC - Oceania 7
AF - Africa 2
Totale 52.273
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 47.559
IT - Italia 1.336
UA - Ucraina 632
DE - Germania 530
IE - Irlanda 515
CN - Cina 392
FR - Francia 312
GB - Regno Unito 182
KR - Corea 137
FI - Finlandia 135
SE - Svezia 126
PL - Polonia 118
RU - Federazione Russa 55
BE - Belgio 27
CA - Canada 22
EU - Europa 21
GR - Grecia 15
IN - India 15
JP - Giappone 15
VN - Vietnam 13
NL - Olanda 10
CH - Svizzera 9
KG - Kirghizistan 8
RO - Romania 8
AU - Australia 6
BR - Brasile 6
CL - Cile 5
ES - Italia 5
PT - Portogallo 5
UZ - Uzbekistan 5
AL - Albania 4
HK - Hong Kong 4
SK - Slovacchia (Repubblica Slovacca) 4
IL - Israele 3
TR - Turchia 3
AT - Austria 2
AZ - Azerbaigian 2
DM - Dominica 2
IQ - Iraq 2
MY - Malesia 2
PE - Perù 2
SG - Singapore 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
BY - Bielorussia 1
CO - Colombia 1
CZ - Repubblica Ceca 1
EG - Egitto 1
HU - Ungheria 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
MX - Messico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
TN - Tunisia 1
TW - Taiwan 1
Totale 52.273
Salva come PNG Salva come JPEG
Città #
Woodbridge 13.874
Wilmington 13.213
Houston 12.126
Fairfield 1.767
Ann Arbor 1.083
Ashburn 793
Seattle 623
Cambridge 608
Chandler 607
Jacksonville 574
Dublin 477
Medford 365
Dearborn 230
Rome 224
Beijing 184
Lawrence 169
New York 123
Milan 121
Kraków 111
San Diego 97
Menlo Park 70
London 40
Norwalk 39
Mülheim 36
Verona 36
Zhengzhou 36
Durham 35
Falls Church 33
Redwood City 32
Turin 30
Shanghai 27
Brussels 26
Naples 25
Mountain View 24
Palo Alto 24
Nanjing 20
San Jose 20
Seoul 20
Florence 19
University Park 19
Helsinki 18
Hefei 17
Council Bluffs 16
Genoa 16
Kunming 16
St Louis 16
Phoenix 15
Sassari 15
Toronto 15
Nürnberg 13
Reggio Calabria 12
Bologna 11
Padova 11
Pisa 11
Redmond 11
Saint Petersburg 11
Catania 10
Engelhard 10
Garden City 10
Hounslow 10
Kilburn 10
Mcallen 10
Pavia 10
Bergamo 9
Creede 9
Wuhan 9
Athens 8
Dong Ket 8
Trento 8
Bari 7
Chengdu 7
Los Angeles 7
Pune 7
Altamura 6
Boardman 6
Del Norte 6
Detroit 6
Guangzhou 6
Islington 6
Jinan 6
Partinico 6
Pescara 6
Sale Marasino 6
Siena 6
Albino 5
Barcellona Pozzo di Gotto 5
Cagliari 5
Chania 5
Chiswick 5
Como 5
Hangzhou 5
Hanoi 5
Lugo 5
Philadelphia 5
Ravenna 5
Rho 5
Warsaw 5
Atlanta 4
Aversa 4
Brescia 4
Totale 48.496
Salva come PNG Salva come JPEG
Nome #
Quality of life in Parkinson’s disease: Italian validation of the Parkinson’s Disease Questionnaire (PDQ-39-IT) 918
malattia di alzheimer e altre demenze diagnosi e terapia integrata. 660
CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia 437
Spontaneous sleep modulates the firing pattern of Parkinsonian subthalamic nucleus 434
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis 427
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. 424
Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a natural population of cognitive intact Parkinson's Disease patients. 420
High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients 417
Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms 415
Cortical hyperexcitability in post-traumatic stress disorder secondary to minor accidental head trauma: a neurophysiologic study 414
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease 410
Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment 410
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease 409
Electrophysiological evidence for visuocognitive dysfunction in younger non Caucasian patients with Parkinson's disease 409
SEPs N30 amplitude in Parkinson's disease and in pharmacologically induced rigidity: relationship with the clinical status 409
Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia 409
Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process 404
Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease 404
The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease 403
Deep brain stimulation of CM/PF of thalamus could be the new elective target for tremor in advanced Parkinson's Disease? 403
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 402
Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease 401
Optic Nerve dysfunction in obstructive sleep apnea: An electrophysiological study 401
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature 400
Curariform peripheral block of muscular tone selectively increases precentral N30 somatosensory evoked potentials component. A pharmacological study carried out on healthy subjects and parkinsonian syndromes 398
Perfusion-weighted dynamic susceptibility (DSC) MRI: basal ganglia hemodynamic changes after apomorphine in Parkinson's disease 396
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus 395
Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study 394
Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients 393
Deep brain stimulation of pedunculopontine tegmental nucleus: role in sleep modulation in advanced Parkinson disease patients: one-year follow-up. 393
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 393
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome 392
Restless legs syndrome and poliomyelitis: New evidences of an old observation? 392
123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study 390
May a suspicious psychiatric disorder hide sporadic hemiplegic migraine? Genetic test as prompting factor for diagnosis 387
Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease 387
Bilateral GPi DBS is useful to reduce abnormal involuntary movements in advanced Parkinson's disease patients, but its action is related to modality and site of stimulation 386
Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. 385
Deep brain stimulation of both subthalamic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study 385
Therapy for dyskinesias in Parkinson’s disease patients 385
Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine 384
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations 384
Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease 383
Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart 383
Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT 382
The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease. 379
An electrophysiological study of D2 dopaminergic actions in normal human retina: a tool in Parkinson's disease 379
Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials 379
Pedunculopontine nucleus stimulation influences REM sleep in Parkinson's disease 377
Involvement of Subcortical Brain Structures During Olfactory Stimulation in Multiple Chemical Sensitivity 376
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients 374
A mixed D1 and D2 antagonist does not replay pattern electroretinogram alterations observed with a selective D2 antagonist in normal humans: relationship with Parkinson's disease pattern electroretinogram alterations 373
Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients - An ambulatory polysomnographic study 372
Effect of apomorphine on cortical inhibition in Parkinson's disease patients: a transcranial magnetic stimulation study 371
Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients 368
Age and stage dependency of P300 latency alterations in non-demented Parkinson's disease patients without therapy 368
Effect of Vigabatrin on motor responses to transcranial magnetic stimulation: An effective tool to investigate in vivo GABAergic cortical inhibition in humans 364
The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease 360
Emotional processing in Parkinson's disease. A study using functional transcranial doppler sonography 360
Catecholamine-based treatment in AD patients: expectations and delusions 360
Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder 359
Motor and non-motor effects of PPN-DBS in PD patients: insights from intra-operative electrophysiology 358
Alexithymia is a non-motor symptom of Parkinson disease 357
Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain 354
Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss? 354
Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease 353
123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms 353
Deep brain stimulation in Parkinson's disease patients: biochemical evidence 352
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. 350
Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in parkinsonian patients 350
CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD 349
Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the 'indirect pathway' 349
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment 348
Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease 347
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.(Reply from the authors) 347
Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: molecular imaging with ¹²³I-MIBG. 347
Neurological complications of pregnancy 346
The effect of deep brain stimulation on the frontal N30 component of somatosensory evoked potentials in advanced Parkinson's disease patients 346
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids 343
The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson's disease. A clinical and electrophysiological study 343
Long term effects of Helicobacter pylori eradication on L-dopa absorption in Parkinson's disease 341
Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease 341
Deep brain stimulation of the pedunculopontine tegmentum and subthalamic nucleus: effects on gait in Parkinson's disease 339
L-dopa modulates motor cortex excitability in Alzheimer's disease patients 338
N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study 338
Increasing doses of l-sulpiride reveal dose- and spatial frequency-dependent effects of D2 selective blockade in the human electroretinogram 338
P3 components evoked by unilateral and bilateral somatosensory stimulation: normative data for the study of neglect syndrome 337
Reduced GABA Content in the Motor Thalamus during effective deep brain stimulation of the subthalamic nucleus 330
Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. 330
A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease 329
Deep brain stimulation of pedunculopontine tegmental nucleus (PPTg) promotes cognitive and metabolic changes: a target-specific effect or response to a low-frequency pattern of stimulation? 327
Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients 325
Multi-target strategy for Parkinsonian patients: the role of deep brain stimulation in the centromedian-parafascicularis complex. 322
Does 123I-MIBG scintigraphy really assist the diagnosis of Parkinson's disease? 322
Antiparkinsonian and anti-levodopa-induced dyskinesia effects obtained by stimulating the same site within the GPi in PD 322
When cognitive decline and depression coexist in the elderly: CSF biomarkers analysis can differentiate Alzheimer's disease from late-life depression 322
Deep brain stimulation (DBS) attentional effects parallel those of l-dopa treatment 321
Grammar improvement following deep brain stimulation of the subthalamic and the pedunculopontine nuclei in advanced Parkinson's disease: A pilot study 320
Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease 318
Commentary: Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease 316
Totale 37.948
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.644
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.644
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20193.083 0 0 0 0 0 0 0 0 0 0 1.483 1.600
2019/202014.804 1.335 1.215 1.147 1.380 1.225 1.511 1.212 1.309 1.310 1.196 857 1.107
2020/20218.487 985 1.094 958 1.071 837 880 1.041 782 214 170 371 84
2021/20222.000 64 249 99 74 69 131 319 90 116 133 149 507
2022/20231.951 211 130 71 211 142 467 183 106 152 36 146 96
2023/20241.374 126 57 113 105 151 205 147 256 69 136 9 0
Totale 53.088